Concepta PLC First myLotus® UK Fertility Clinic collaboration (0442O)
September 30 2019 - 1:01AM
UK Regulatory
TIDMCPT
RNS Number : 0442O
Concepta PLC
30 September 2019
RNS release: 30 September 2019
Concepta announces first myLotus(R) UK Fertility Clinic
collaboration
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of the proprietary self-test
platform ("myLotus(R)"), the most accurate home-use fertility
tracking and pregnancy testing system available on the U.K. market,
announces today its first UK Fertility Clinic collaboration with
Manchester Fertility.
The collaboration with Manchester Fertility marks the first U.K.
fertility clinic to use myLotus(R) to advance the clinics
Intrauterine Insemination (IUI) procedures allowing women to
monitor their fertility progress at home prior to presenting for
insemination.
myLotus(R) the revolutionary home based, self-test product was
launched in the UK in November 2018 with early 'trying to conceive'
users providing personal video feedback and testimonials on their
menstrual cycle hormone changes and profile ('signatures') enabling
these women greater visibility and better understanding of their
menstrual cycle and fertility journey (www.mylotus.com). In March
the Company announced its first supply agreement with Boots UK
(part of Walgreens Boots Alliance) and in May its first myLotus
pregnancies and user testimonials.
Manchester Fertility are the leading provider of IUI in the
North of England and treat more than 600 women for IUI treatments
annually. The myLotus(R) IUI procedure will be available to women
from October 2019. myLotus(R) is expected to provide much greater
accuracy around user readiness for insemination and efficiency of
operation and preparation for IUI across natural and stimulated
cycles.
The advance of myLotus(R) comes at a time when there is a
national shortage of hormone replacement therapy (HRT) and a
greater need to focus on natural and modified natural fertility
procedures.
myLotus(R) empowers women to self-test their personalised
hormone levels and identify their optimal fertile days thereby
improving their chances of naturally getting pregnant. myLotus(R)
enables women to monitor their fertile phase as part of their
menstrual cycle and is the only home test to 'quantitatively'
measure hormone levels and the 'rate-of-change' of these levels
preceding ovulation to help aid a natural or assisted conception.
Users measure, record and track their hormone levels and follow
their fertility journey in an accompanying free downloadable app
available in iOS and Android formats via the www.mylotus.com
website.
myLotus(R) is available to women who are planning to start a
family or for those who have previously struggled to naturally
conceive, enabling couples an alternative prior to considering IVF
treatment. The Company expects to release further hormone health
and wellbeing tests to complement its fertility offering early next
year.
Matthew Walls, Chairman said: "We are extremely proud and
delighted to announce our first collaboration with Manchester
Fertility and the advance of myLotus for use in assisted
reproduction cycles. We expect to build our fertility clinic
developments over the short term and look forward to supporting all
our users on their pregnancy journey."
Jonathan Koslover, Managing Director, Manchester Fertility said:
"As one of the UKs leading fertility clinics we pride ourselves on
being innovative and pioneering to help patients on every step of
their fertility journey. We are delighted to be the first clinic in
the North of England to offer myLotus(R) and further enhance the
treatments we offer. As one of the most reputed fertility clinics
we also have access to our own extensive sperm bank, ensuring the
highest quality of care and no waiting times, so patients can start
trying for their family straight away."
Enquiries
Company: www.conceptaplc.com, Product: www.mylotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
Claire Course, Communications Coordinator, Manchester
Fertility
Tel: 0161 300 2730
Email: clairec@manchesterfertility.com
Website: www.manchesterfertility.com
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
About Concepta PLC:
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalised mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKCDQABKDDCB
(END) Dow Jones Newswires
September 30, 2019 02:01 ET (06:01 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024